Novo Nordisk A/S
XBER:NOV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.985
86.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Wall Street
Price Targets
NOV Price Targets Summary
Novo Nordisk A/S
According to Wall Street analysts, the average 1-year price target for
NOV
is 54.48 EUR
with a low forecast of 36.13 EUR and a high forecast of 100.16 EUR.
Operating Income
Forecast
Operating Income Estimate
Novo Nordisk A/S
For the last 13 years the
compound annual growth rate for
Novo Nordisk A/S's operating income is
15%.
The projected
CAGR
for the next 4 years is
4%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NOV's stock price target?
Price Target
54.48
EUR
According to Wall Street analysts, the average 1-year price target for
NOV
is 54.48 EUR
with a low forecast of 36.13 EUR and a high forecast of 100.16 EUR.
What is Novo Nordisk A/S's Revenue forecast?
Projected CAGR
7%
For the last 13 years the
compound annual growth rate for
Novo Nordisk A/S's revenue is
12%.
The projected
CAGR
for the next 4 years is
7%.
What is Novo Nordisk A/S's Operating Income forecast?
Projected CAGR
4%
For the last 13 years the
compound annual growth rate for
Novo Nordisk A/S's operating income is
15%.
The projected
CAGR
for the next 4 years is
4%.
What is Novo Nordisk A/S's Net Income forecast?
Projected CAGR
6%
For the last 13 years the
compound annual growth rate for
Novo Nordisk A/S's net income is
15%.
The projected
CAGR
for the next 4 years is
6%.